Factors associated with remission included older age, HbA1c, weight loss from diagnosis to 2019, previous bariatric surgery
WEDNESDAY, Nov. 3, 2021 (HealthDay News) — About 5 percent of adults aged 30 years and older in Scotland with type 2 diabetes were in remission in 2019, according to a study published online Nov. 2 in PLOS Medicine.
Mireille Captieux, M.B.Ch.B., M.P.H., from the University of Edinburgh in the United Kingdom, and colleagues conducted a cross-sectional study to estimate the prevalence of type 2 diabetes remission in adults in Scotland aged 30 years and older. Remission of type 2 diabetes was defined as all hemoglobin A1c (HbA1c) values <48 mmol/mol in the absence of glucose-lowering therapy for a continuous duration of ≥365 days before the last recorded HbA1c in 2019 and was assessed between Jan. 1 and Dec. 31, 2019. Data were included for 162,316 individuals, all of whom had at least one HbA1c value of ≥48 mmol/mol at or after type 2 diabetes diagnosis.
The researchers found that 7,710 people (4.8 percent) were in remission of type 2 diabetes. Factors associated with remission included age (odds ratio, 1.48 for ≥75 versus 45 to 54 years), HbA1c (odds ratio, 1.31 for <48 versus 48 to 52 mmol/mol at diagnosis), no previous history of glucose-lowering therapy (odds ratio, 14.6), weight loss from diagnosis to 2019 (odds ratio, 4.45 for ≥15 kg versus 0 to 4.9 kg weight gain), and previous bariatric surgery (odds ratio, 11.9).
“We have been able to show, for the first time, that one in 20 people in Scotland with type 2 diabetes achieve remission,” Captieux said in a statement. “This is higher than expected and indicates a need for updated guidelines to support clinicians in recognizing and supporting these individuals.”
Two authors disclosed financial ties to the pharmaceutical industry.
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis